Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.

NCT01975142 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

155

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer, HER2 Negative Primary Tumor

Interventions

DRUG: Trastuzumab - Emtansine

Sponsor

Institut Curie